Study on the treatment of patients with locally advanced lung adenocarcinoma ALk fusion taking crizotinib

For patients with locally advanced lung adenocarcinomaALK fusion, Crizotinib, as a targeted therapy, has shown significant therapeutic effects.

Crizotinib is a tyrosine kinase inhibitor that mainly targetsALK fusion protein. In lung adenocarcinoma, ALK fusion mutation is a common genetic mutation. This mutation causes the ALK protein to combine with other proteins to form abnormal fusion proteins, thereby promoting the growth and spread of tumor cells. Crizotinib inhibits the proliferation and survival of tumor cells by specifically recognizing and binding to the ALK fusion protein and blocking its signaling pathway.

Multiple clinical trial data show that crizotinib shows significant efficacy in the treatment ofALK fusion-positive locally advanced or metastatic lung adenocarcinoma patients. For example, in a randomized, multicenter, open-label phase 3 clinical trial, the response rate and progression-free survival were better in the crizotinib group than in the chemotherapy group.

In clinical practice, crizotinib has been widely used to treat patients with ALK fusion-positive locally advanced lung adenocarcinoma. After receiving crizotinib treatment, many patients have significantly reduced or stabilized tumor lesions, prolonged progression-free survival, and improved quality of life.

Before using crizotinib, patients need to undergo genetic testing to confirm the presence ofALK fusion mutations. Only patients with ALK fusion positivity are suitable for treatment with crizotinib.

Crizotinib may cause a series of side effects, such as visual impairment, nausea, vomiting, diarrhea, etc. Most of these side effects are mild to moderate and can be alleviated by appropriate dose adjustment or symptomatic treatment. However, a small number of patients may experience serious side effects, such as interstitial lung disease, QT interval prolongation, etc., which require close monitoring and prompt treatment.

Some patients may develop drug resistance after taking crizotinib for a period of time. Therefore, it is necessary to closely monitor changes in the patient's condition during treatment and adjust treatment plans in a timely manner to cope with drug resistance challenges.

For some locally advanced lung adenocarcinomasFor patients with ALK fusion, crizotinib combined with other targeted drugs or chemotherapy drugs may be able to produce better therapeutic effects. However, combination therapy needs to be carried out under the guidance of a doctor to ensure safety and effectiveness.